510(k) K182703
K182703 is an FDA 510(k) premarket notification submitted by Serosep , Ltd. for the device "EntericBio Dx Assay". The FDA issued a decision of Substantially Equivalent on Jun 19, 2019. The device falls under product code PCH (Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System), a Class II device regulated under 21 CFR 866.3990.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Jun 19, 2019
- Date Received
- Sep 27, 2018
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System
- Device Class
- Class II
- Regulation Number
- 866.3990
- Review Panel
- MI
- Submission Type
- 510(k)
A gastrointestinal pathogen panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple gastrointestinal microbial nucleic acids extracted from human stool specimens. The detection and identification of a specific gastrointestinal microbial nucleic acid from individuals exhibiting signs and/or symptoms of gastrointestinal infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation and other laboratory findings.
Need the full FDA record for Serosep , Ltd.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.